Viking releases new data on VK2735 in prediabetes, metabolic syndrome

[Obesity and overweight from overeating. Big belly tied with measuring tape as a gift. Body fat from candies and sweets]
Alona Siniehina/iStock via Getty Images

* Viking Therapeutics (VKTX [https://seekingalpha.com/symbol/VKTX]) said that an analysis of phase 2 data on an injectable version of its GLP-1/GIP receptor agonist VK2735 showed positive improvements in prediabetes and metabolic syndrome.
* The analysis of the 13-week VENTURE trial found that at the end of it, 78% of patients treated with the drug who were prediabetic at baseline had successfully shifted to normal glycemic status. The figure was 29% for those on placebo.
* Also, 68% of those receiving VK2735 who were considered having metabolic syndrome at the outset no longer did [https://seekingalpha.com/pr/20296425-viking-therapeutics-highlights-clinical-data-from-vk2735-obesity-program-in-presentation-at], compared to 38% on placebo.
* The subcutaneous version of VK2735 is currently in phase 3 for obesity. A pill version for the same indication is in phase 2.

MORE ON VIKING THERAPEUTICS

* Sell Novo Nordisk And Buy Viking Therapeutics [https://seekingalpha.com/article/4836794-sell-novo-nordisk-and-buy-viking-therapeutics]
* Viking Therapeutics: A Look At The Catalysts Ahead [https://seekingalpha.com/article/4834288-viking-therapeutics-a-look-at-catalysts-ahead]
* Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith) [https://seekingalpha.com/article/4832439-viking-therapeutics-q3-earnings-what-we-learned-and-why-we-should-keep-faith]
* Viking Therapeutics outlines completion of VANQUISH-1 enrollment by year-end while advancing novel VK2735 maintenance dosing study [https://seekingalpha.com/news/4507233-viking-therapeutics-outlines-completion-of-vanquishminus-1-enrollment-by-year-end-while]
* Viking sees enrollment in late-stage trial for oral obesity pill completed in Q4 [https://seekingalpha.com/news/4507222-viking-sees-enrollment-late-stage-trial-f-oral-obesity-pill-completed-q4]